Saprisartan is an Type-1 angiotensin II (AT1) receptor antagonist, its chemical structure comes from losartan. This drug is a noncompetitve antagonism of AT1. It blocks the renin-angiotensin-aldosterine system (RAAS) when binding the AT1 receptor that mediates the important actions of angiotensin II. By inhibiting those actions, saprosartan leads to a decrease in sodium reabsorpion and a decrease in vasoconstriction, those two actions decrease the blood pressure.
References
Saprisartan Pathway References
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M: DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037.
Timmermans PB: Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics. Hypertens Res. 1999 Jul;22(2):147-53. doi: 10.1291/hypres.22.147.
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.